Elsiglutide in the primary prevention of chemotherapy (CT)-induced diarrhea in patients with colorectal cancer (CRC) receiving 5-fluorouracil (5-FU)-based CT: A multinational, randomized, double-blind, placebo-controlled study

Karthaus, Meinolf and Fedyanin, Mikhail and Bondarenko, Igor and Chessari, Salvatore and Spezia, Riccardo and Giorgino, Ruben (2017) Elsiglutide in the primary prevention of chemotherapy (CT)-induced diarrhea in patients with colorectal cancer (CRC) receiving 5-fluorouracil (5-FU)-based CT: A multinational, randomized, double-blind, placebo-controlled study. Journal of Clinical Oncology, 35 (15). p. 10101. ISSN 0732-183X (Print) ; 1527-7755 (Electronic) ; 0732-183X (Linking)

Text Elsiglutide in the primary prevention of chemotherapy.docx Download (17kB)

Abstract

Background: Diarrhea is a burdensome toxicity of 5-FU-based regimens and may lead to CT dose intensity reduction. We investigated the efficacy of 3 subcutaneous (sc) doses of elsiglutide (a GLP-2 analog) vs. placebo and vs. each other, in the primary prevention of CT induced diarrhea in patients (pts) with CRC receiving FOLFOX or FOLFIRI. Methods: Pts were randomized equally to receive placebo or elsiglutide 10, 20, or 40 mg sc on days (d) 1–4 of the first 2 CT cycles and were followed up in cycle 3 for safety only. ...

Item Type:	Article
Subjects:	Oncology
Divisions:	Departments > Department of Oncology and Medical Radiology
Depositing User:	Елена Шрамко
Date Deposited:	07 Sep 2017 13:11
Last Modified:	07 Sep 2017 13:11
URI:	http://repo.dma.dp.ua/id/eprint/1925

Actions (login required)

View Item